Claire Dossier

Claire Dossier

Auto-generated profile, based on publicly available information

Claire Dossier

Pediatric Nephrology, Hôpital Universitaire Robert Derbre, Paris, France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2023 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
CDClaire Dossier
Claire Dossier
SBStéphanie Bonneric
Stéphanie Bonneric
VBVéronique Baudouin
Véronique Baudouin
TKThérésa Kwon
Thérésa Kwon
BPBenjamin Prim
Benjamin Prim
JHJulien Hogan
Julien Hogan
Background: B-cell depletion with rituximab induces sustained remission in children with steroid-dependent or frequently relapsing nephrotic syndrome. However, most patients relapse after B-cell recovery, and some patients do not achieve B-cell depletion. Obinutuzumab is a second-generation anti-CD20 antibody designed to overcome such situations in B-cell malignancies and was recently reported to be safe and effective in other autoimmune diseases affecting the kidneys. Methods: We retrospectively report 41 children with steroid-dependent or frequently relapsing nephrotic syndrome treated with a single low-dose infusion of obinutuzumab at Robert-Debre Hospital between April 2018 and December 2020. Participants were treated because of rituximab resistance or relapse after rituximab and received a single infusion of 300 mg/1.73 m2 obinutuzumab with cessation of oral immunosuppressors within 2 months. Results: B-cell depletion was achieved in all participants and lasted a median of 8.3 months (interquartile range, 6.4–11.1), a duration exceeding that for last rituximab treatment. At 12 and 24 months, 92% (38/41) and 68% (28/41) of patients, respectively, were in sustained remission. Mild infusion reactions occurred in five participants (12%) and neutropenia in nine (21%). No significant decrease in IgG level was reported during treatment, and whereas IgM levels decreased in 34 patients (83%), they were normal at last follow-up in 32 (78%). Conclusions: These results identified low-dose obinituzumab as a promising treatment option in children with steroid-dependent or frequently relapsing nephrotic syndrome, including those resistant to rituximab. The tolerance profile of obinutuzumab was similar to that of rituximab, but hemogram and immunoglobulin levels should be monitored.

24 October 2016 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
CDClaire Dossier
Claire Dossier
NLNathanael Lapidus
Nathanael Lapidus
FBFlorian Bayer
Florian Bayer
ASAnne-Laure Sellier-Leclerc
Anne-Laure Sellier-Leclerc
OBOlivia Boyer
Olivia Boyer
GDGeorges Deschênes
Georges Deschênes

14 December 2018 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
CDClaire Dossier
Claire Dossier
JDJean-Daniel Delbet
Jean-Daniel Delbet
OBOlivia Boyer
Olivia Boyer
PDPatrick Daoud
Patrick Daoud
BMBettina Mesples
Bettina Mesples
GDGeorges Deschênes
Georges Deschênes

24 August 2023 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
MMMarie Sophie Meuleman
Marie Sophie Meuleman
PVPaula Vieira-Martins
Paula Vieira-Martins
CSCarine El Sissy
Carine El Sissy
VAVincent AUDARD
Vincent AUDARD
VBVéronique Baudouin
Véronique Baudouin
SCSophie Chauvet
Sophie Chauvet
Background: C3 glomerulopathy and idiopathic immunoglobulin-mediated membranoproliferative GN (Ig-MPGN) are rare complement-mediated kidney diseases. Inherited forms of C3 glomerulopathy/Ig-MPGN are rarely described. Methods: Three hundred ninety-eight patients with C3 glomerulopathy (n=296) or Ig-MPGN (n=102) from a national registry were screened for three complement genes: factor H (CFH), factor I (CFI), and C3. Patients with rare variant (minor allele frequency <0.1%) were included. Epidemiologic, clinical, and immunologic data at diagnosis and kidney outcomes of patients were retrospectively collected. Results: Fifty-three different rare variants, including 30 (57%), 13 (24%), and ten (19%) in CFH, CFI, and C3 variants, were identified in 66/398 (17%) patients. Thirty-eight (72%) variants were classified as pathogenic, including 20/30 (66%) and 11/13 (84%) variants in CFH and CFI, respectively, impairing synthesis of factor H or factor I regulators. Fifteen of 53 (27%) variants were of unknown significance. At diagnosis, 69% of patients were adult (median age of 31 years). With the exception of biologic stigma of thrombotic microangiopathy, which was more frequent in patients with CFI variants (5/14 [36%] versus 1/37 [3%] and 0% in the CFH group and C3 group, respectively, P < 0.001), the clinical and histologic features were similar among the three variants groups. The kidney outcome was poor regardless of the age at onset and treatment received. Sixty-five percent (43/66) of patients with rare variant reach kidney failure after a median delay of 41 (19–104) months, compared with 28% (55/195) after a median delay of 34 (12–143) months in the nonvariant group. Among 36 patients who received a kidney transplant, 2-year recurrence was frequent, occurring in 39% (12/31), without difference between variant groups, and led to graft failure in three cases. Conclusions: In our cohort, 17% of C3 glomerulopathy/Ig-MPGN cases were associated with rare variants in the CFH, CFI, or C3 genes. In most cases, a quantitative deficiency in factor H or factor I was identified. The presence of a rare variant was associated with poor kidney survival. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_11_08_CJN0000000000000252.mp3

3 April 2024 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
RPRomain Pszczolinski
Romain Pszczolinski
CACécile Acquaviva
Cécile Acquaviva
IBInsaf Berrahal
Insaf Berrahal
NBNathalie Biebuyck
Nathalie Biebuyck
SBStéphane Burtey
Stéphane Burtey
BMBruno Moulin
Bruno Moulin
Primary hyperoxalurias (PH) are extremely rare genetic disorders characterized by clinical heterogeneity. Delay in diagnosing these conditions can have detrimental effects on patient outcomes. The primary objective of this study is to assess the current diagnostic delay for PH. This nationwide, observational and retrospective study included patients who received a genetic diagnosis of PH types 1, 2 and 3 between 1 January 2015 and 31 December 2019. Diagnostic delay was defined as the duration between the onset of symptoms and the time of genetic diagnosis. A total of 52 patients (34 children and 18 adults) were included in the study, with 40 PH1 (77%), 3 PH2 (6%) and 9 PH3 (17%). At the time of diagnosis, 12 patients (23%) required dialysis. Among the PH1 patients, the predominant symptom at onset in adults was renal colic (79% of cases), whereas symptoms in children were more diverse (renal colic in 17% of cases). The diagnostic delay was significantly shorter in children compared with adults [median (interquartile range)]: 1.2 (0.1–3.0) versus 30 (17–36) years, respectively (P < .0001). RNA interference was utilized in 23 patients (58%). Five individuals (13%) underwent double liver–kidney transplantation, and five (13%) received isolated kidney transplantation, with lumasiran therapy in four patients. For PH2 and PH3 patients, the diagnostic delay ranges from 0 to 3 years, with renal colic as first symptom in 33% of cases. This extensive and recent cohort of PH underscores the considerable delay in diagnosing PH, particularly in adults, even in a country with a dedicated organization for enhancing the overall management of rare diseases. These findings reinforce the imperative for increased awareness among relevant specialties regarding the evaluation of urolithiasis.

5 July 2021 in Journal Of Nephrology
Verified
Journal Article
Closed access
PDF file
MMMarie-Sophie Meuleman
Marie-Sophie Meuleman
SGSophie Guilmin-Crépon
Sophie Guilmin-Crépon
AHAurélie Hummel
Aurélie Hummel
EDEric Daugas
Eric Daugas
ADAgnes Dumas
Agnes Dumas
HMHélène Mellerio
Hélène Mellerio
Background Long-term psychosocial outcomes and health-related quality of life (HRQOL) in adults with pediatric onset of frequently relapsing or steroid-dependent idiopathic nephrotic syndrome (FRNS or SDNS) remain to be determined. Methods In this prospective cohort study, 59 adults with pediatric onset of FRNS/SDNS and persistent active glomerular disease in adulthood completed the GEDEPAC-2 questionnaire exploring 11 well-being domains. Data were compared to the French general population (FGP) with standardized incidence ratio ([SIR]; adjusted for period, age, gender). Regression models were performed to identify predictive factors of psychosocial well-being. Results In 82% of cases, the questionnaire was completed while the participants (n = 59; 47 men; median age = 32 years; median number of relapses = 13) were in complete remission (under specific therapy in 76% of cases). Participants had higher educational degree than in the FGP (SIR = 6.3; p < 0.01) and more frequently a managerial occupation (SIR = 3.1; p < 0.01). Social integration was acceptable with regard to marital status and experience of sexual intercourse, but experiences of discrimination were far more frequent (SIR = 12.5; p < 0.01). The SF-12 mental component summary (MCS) score was altered (Z-score = − 0.6; p < 0.01) and mean multidimensional fatigue inventory (MFI-20) global fatigue score appeared high (12). Transfer from pediatric to adult healthcare was followed by a period of discontinued care for 33% of participants. Multivariate analysis revealed a close relationship between MFI-20, physical health, and MCS. Conclusions This study shows that pediatric onset FRNS and SDNS may have a long-term negative impact on mental HRQOL and highlights the impact of fatigue, which is often not adequately considered in routine care. Graphic abstract